Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2015

View Archived Issues

Safety and toxicity results presented for pralatrexate plus oxaliplatin combination treatment

Cabozantinib S-malate shows limited activity in advanced CCA patients

Combination of pimasertib and gemcitabine fails to improve PFS

PF-04136309 and FOLFIRINOX shows no additional toxicity in pancreatic adenocarcinoma

Selective cannabinoid CB1 receptor antagonism improves diabetic nephropathy

Jakavi recommended for approval in Europe for polycythemia vera

Senshio approved in Europe for vulvar and vaginal atrophy

Data and safety monitoring board recommends continuation of phase II masitinib

ISIS-416858 shows potential to decrease postoperative thrombosis

Researchers at BMS disclose new ROCK-2 inhibitors

Calibr patents novel dimeric compounds for COPD and cystic fibrosis

Millennium Pharmaceuticals reports SUMO-activating enzyme inhibitors

New cyclin-G-associated kinase ligands designed at KU Leuven

ZIOPHARM Oncology presents ongoing projects

Scientists in Japan prepare and test novel P2X4 antagonists for pain

Merck & Co. completes Cubist tender offer

Array BioPharma to acquire worldwide rights to encorafenib

EMA committee recommends approval of Saxenda for weight management

EMA recommends approval of Abraxane for NSCLC

FDA accepts Praluent BLA for priority review

European CHMP recommends new approval of Eylea

Neomed receives approval to begin phase I trial of NEO-6860

Galapagos receives grant for antibiotic research

FDA approves Bexsero meningitis B vaccine

The Medicines Company receives CHMP recommendations for three acute care products

FDA grants fast track designation to intrathecally idursulfase

Cubist's tedizolid phosphate recommended for approval in E.U. for ABSSSI

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026